overcome with the use of preventative antimicrobial treatment; however, a recent study has shown that in rats with a high cholesterol diet, the imbalance in gut microbiota, caused by certain antibiotics, can aggravate already existing liver injuries [4] .
Despite the mounting evidence that dysregulation of miRNAs plays a role in the development of many diseases, its transfer to clinics has been sparse. A major contributing factor is the delivery of miRNA alongside the poor pharmacokinetics of synthetic miRNA. Here, Chen et al. (2016) have built on the knowledge that miRNA-146a-5p plays a key role in hepatic fibrosis.
The study here suggests that the use of a mimic miR-146-5p may be of benefit in liver fibrosis mediated by inflammatory insult. This is suggested to work by altering the expression of key mediators downstream of IRAK and NF-Kβ activation and thus altering key ECM genes that are activated in fibrosis. This is interesting as targeting this pathway may be important not only in liver fibrosis but in other fibrotic diseases such as systemic sclerosis where such pathways are altered. We have found that, in systemic sclerosis, NF-KB is altered and mediates skin fibrosis [5] . In such diseases, there are also altered levels of inflammatory cytokines and chemokines. Targeting these distinct organs with a miR-146-5p mimic could prove appealing, especially in the early stages of the disease where an inflammatory response primarily dominates before the preceding reparative phase. What is less clear is, if enhancing, such microRNAs would impede the normal inflammatory response needed to cease and desist bacterial dissemination. Further testing in animal models of fibrosis using synthetic miRs will yield the answers. However, barriers such as the stability, resistance to degradation and selectivity of the mimics are still to be overcome. Targeting the miRs to the correct cell and tissue can possibly be improved by conjugating to antibodies selective for specific antigen on the target cell. Furthermore, redundancy of miRs may also be a barrier to therapeutic intervention.
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